Field
    Medical Drug, Method

Keywords
     Acute myelocytic leukemia (AML), Cytarabine (Ara-C), Antileukemic activity, Apoptotic activity, 
     Antileukemia agent, Method of removing leukemia cells

Advantages
    <Evaluation of stability of peptide in human serum>
    FNIII14 rapidly lost the activity in 2 hours. The activity decreased to about 60% after 20 hours.
    DG-FNIII14 shows stability as long as 60 hours, and tends to be decomposed after 50 hours or 
    later. 
    <Evaluation on anticancer agent promotion activity>
    It was confirmed that an inhibitory effect in terms of IC50 of AraC in the presence of DG-FNIII14
    is about 100 times as large as in the absence of the peptide, and about 10 times as large as in the
    presence of FNIII14.
    <Good combination effect>
    The line showing a combination use with DG-FNIII14 greatly curves downward, indicating that a
    synergetic effect is obtained. The combination index was as extremely high as 0.188 at an Ara-C
    concentration of 106 M, which falls within an effective concentration range of the medicinal drug in
    blood. 

Abstract
Provided are an agent for promoting the activity of an anticancer agent capable of promoting the therapeutic effect of the anticancer agent to be used in combination and an anticancer composition containing the same.  An agent for promoting the activity of an anticancer agent containing, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, which is a polypeptide FNIII14 derived from a human tenascin C fibronectin III-like repeat sequence (FNIII) and having an amino acid sequence as set forth in SEQ ID NO:1, in which at least one of the amino acid residues at positions 1 to 13 is a D-form amino acid residue.

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: